Gilead Sciences Announces Third Quarter 2019 Dividend
Get Alerts GILD Hot Sheet
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2.3%
Revenue Growth %: +4.4%
Join SI Premium – FREE
FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company’s Board of Directors has declared a cash dividend of $0.63 per share of common stock for the third quarter of 2019. The dividend is payable on September 27, 2019, to stockholders of record at the close of business on September 13, 2019. Future dividends will be subject to Board approval.
About Gilead Sciences
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.
For more information on Gilead Sciences, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190730005938/en/
Investors
Robin Washington
(650) 522-5688
Sung Lee
(650) 524-7792
Source: Gilead Sciences, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Orca Bio’s TREGZI™ Receives U.S. FDA Approval as First and Only Precision-Engineered Cell Therapy for Allogeneic Transplant in Adults with Hematological Malignancies
- Kitsault Energy: A Nation-Building Opportunity to Increase Canada's GDP, Exports, and Global Competitiveness
- Shane Lukas’ TEDx Talk Examines the Hidden Cost of Values Conflict and Its Impact on Stress and Decision-Making
Create E-mail Alert Related Categories
Business Wire, Press ReleasesRelated Entities
Twitter, DividendSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share